Severity: Warning
Message: fopen(/var/lib/php/sessions/ci_sessiondjeft2otu034skldm9i0v0v7554vfa1m): Failed to open stream: No space left on device
Filename: drivers/Session_files_driver.php
Line Number: 177
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
Severity: Warning
Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)
Filename: Session/Session.php
Line Number: 137
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
155 results match your criteria: "MD Anderson Cancer Center Madrid[Affiliation]"
JCO Glob Oncol
November 2024
Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN.
Purpose: To better understand immigration disparities among a Spanish Early-Onset Colorectal Cancer (SECOC) subset, according to the country of origin.
Patients And Methods: We selected 250 consecutive participants from the SECOC consortium. Data on baseline patient and tumor characteristics, family history of colorectal cancer (CRC), and follow-up were collected.
Sci Rep
November 2024
Translational Research, Fundación MD Anderson International España. Madrid, 28033, Madrid, Spain.
ESMO Open
October 2024
Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
• This Clinical Practice Guideline provides key recommendations for managing rare endocrine tumours. • Neuroendocrine neoplasms of different origins, parathyroid carcinoma and intrathyroid thymic neoplasms are included. • The guideline covers clinical imaging and pathological diagnosis, staging and risk assessment, treatment and follow-up.
View Article and Find Full Text PDFGynecol Oncol
December 2024
HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Laboratorio de Innovación en Oncología, Instituto de Investigación Sanitaria HM Hospitales, Madrid, Spain. Electronic address:
Background: Granulosa cell ovarian tumors (GCT) are orphan disease with limited treatments. Hormone therapy is a potential treatment, due to the overexpression of hormone receptors in most tumors. This study explores the activity of the antiandrogen, enzalutamide, in metastatic cases.
View Article and Find Full Text PDFAnn Surg Oncol
January 2025
Peritoneal Surface Malignacies Unit, CHU Moises Broggi, Barcelona, Spain.
Introduction: Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy has become standard for resectable peritoneal surface malignancies. CRS aims to achieve complete resection of macroscopic disease through peritonectomy procedures and visceral resections. The pelvis is very frequently involved in peritoneal malignancies, making surgical techniques that ensure complete tumor removal an essential part of CRS.
View Article and Find Full Text PDFClin Transl Oncol
October 2024
Instituto de Investigación Sanitaria HM Hospitales (IISHM), Madrid, Spain.
Background And Purpose: Despite that incorporating antiangiogenic in combination with immune-checkpoint inhibitors as the standard first-line treatment for advanced clear cell renal cell cancer (ccRCC) yields promising outcomes, these regimens often lead to significant toxicity. However, a subgroup of patients has shown responsiveness to VEGFR tyrosine-kinase inhibitors (TKIs) in monotherapy, leading to the question of whether employing combination therapies can significantly enhance overall survival in all patients over monotherapy. Thus, we aim to identify gene expression signatures that can predict TKI response within subpopulations that might benefit from single-agent therapies, to minimize unnecessary exposure to combination therapies and their associated toxicities, as well as to discover new potential therapeutic targets to improve ccRCC treatment.
View Article and Find Full Text PDFTarget Oncol
November 2024
Medical Oncology Unit, Macerata Hospital, Macerata, Italy.
Target Oncol
November 2024
Oncology Unit, Macerata Hospital, Macerata, Italy.
Int J Cancer
December 2024
Oncology Unit, Macerata Hospital, Macerata, Italy.
Sci Rep
August 2024
Medical Oncology Unit, Macerata Hospital, Macerata, Italy.
The addition of metastasis-directed radiotherapy (MDRT) to immunotherapy in patients with advanced urothelial carcinoma (aUC) has shown promising results. We report the real-world data from the ARON-2 study (NCT05290038) on the impact of conventional (CRT) or stereotactic body radiotherapy (SBRT) on the outcome of aUC patients receiving pembrolizumab after platinum-based-chemotherapy. Medical records of 837 patients were reviewed from 60 institutions in 20 countries.
View Article and Find Full Text PDFCancers (Basel)
July 2024
Hepatobiliary Surgery and Liver Transplant Unit, Gregorio Marañón University Hospital, 28007 Madrid, Spain.
Peritoneal sarcomatosis is a rare malignant disease with a poor prognosis, secondary to peritoneal dissemination of abdominopelvic soft tissue sarcomas. Its rarity, together with the characteristic histological heterogeneity and the historically poor response to systemic treatments, has prevented the establishment of widely accepted treatment criteria with curative intent. In this sense, radical cytoreductive surgery (CRS) with peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC), widely used in peritoneal carcinomatosis with excellent results, have not had the same evolutionary development in patients with peritoneal sarcomatosis.
View Article and Find Full Text PDFNat Commun
August 2024
Medical Oncology Department. Hospital Universitario 12 de Octubre, Madrid, Spain.
Cancers (Basel)
July 2024
Department of Medical Oncology, Instituto de Investigación Imas12, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Eur Urol
December 2024
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mod Pathol
September 2024
Translational Research, MD Anderson Cancer Center Foundation, Madrid, Spain; Pathology Department, MD Anderson Cancer Center Madrid, Madrid, Spain. Electronic address:
As around 25% to 30% of classical Hodgkin lymphoma (cHL) patients with advanced stages do not respond to standard therapies, the tumor microenvironment of cHL is one avenue that may be explored with the aim of improving risk stratification. CD4+ T cells are thought to be one of the main cell types in the tumor microenvironment. However, few immune signatures have been studied, and many of these lack related spatial data.
View Article and Find Full Text PDFCancer Immunol Immunother
June 2024
Oncology Unit, Macerata Hospital, Macerata, Italy.
J Neuroendocrinol
August 2024
Department of medical oncology, EURACAN and ENETS Center of Excellence, Hospices Civils de Lyon, Lyon, France.
Lung carcinoid tumours are neuroendocrine neoplasms originating from the bronchopulmonary tract's neuroendocrine cells, accounting for only 1%-3% of all lung cancers but 30% of all neuroendocrine tumours. The incidence of lung carcinoids, both typical and atypical, has been increasing over the years due to improved diagnostic methods and increased awareness among clinicians and pathologists. The most recent WHO classification includes a subgroup of lung carcinoids with atypical morphology and higher mitotic count and/or Ki67 labelling index.
View Article and Find Full Text PDFSci Rep
May 2024
Division of Hematology, National Taiwan University Hospital, Taipei, Taiwan.
The European Leukemia Net recommendations provide valuable guidance in treatment decisions of patients with acute myeloid leukemia (AML). However, the genetic complexity and heterogeneity of AML are not fully covered, notwithstanding that gene expression analysis is crucial in the risk stratification of AML. The Stellae-123 score, an AI-based model that captures gene expression patterns, has demonstrated robust survival predictions in AML patients across four western-population cohorts.
View Article and Find Full Text PDFTarget Oncol
July 2024
Oncology Unit, Macerata Hospital, Macerata, Italy.
Background: About 20% of patients with renal cell carcinoma present with non-clear cell histology (nccRCC), encompassing various histological types. While surgery remains pivotal for localized-stage nccRCC, the role of cytoreductive nephrectomy (CN) in metastatic nccRCC is contentious. Limited data exist on the role of CN in metastatic nccRCC under current standard of care.
View Article and Find Full Text PDFCancer Immunol Immunother
April 2024
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Eur J Cancer
May 2024
Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Clin Transl Oncol
August 2024
GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Background: Retrospective data suggest an association between bevacizumab efficacy and the incidence of arterial hypertension (AHT). Additionally, epigenetic mechanisms have been related to AHT.
Methods: This prospective observational study conducted by GEICAM Spanish Breast Cancer Research Group included metastatic breast (MBC) or colorectal (mCRC) cancer patients treated with bevacizumab-containing chemotherapy as first-line treatment.
Eur Urol Oncol
October 2024
Oncology Unit, Macerata Hospital, Macerata, Italy.
Background And Objective: Papillary renal cell carcinoma (pRCC) is the most frequent histological subtype of non-clear cell RCC (nccRCC). Owing to the heterogeneity of nccRCC, patients are often excluded from large phase 3 trials focused on clear cell RCC, so treatment options for nccRCC remain limited. Our aim was to investigate the efficacy of first-line treatment with tyrosine kinase inhibitors (TKIs) or immuno-oncology (IO)-based combinations in patients with pRCC.
View Article and Find Full Text PDFEur J Surg Oncol
April 2024
Paseo de la Habana, 190, 28036, Madrid, Spain.
Introduction: The knowledge of BRCA status offers a chance to evaluate the role of the intraperitoneal route in patients selected by biomolecular profiles after primary cytoreduction surgery in advanced ovarian cancer.
Materials And Methods: We performed a retrospective, multicenter study to assess oncological outcomes depending on adjuvant treatment (intraperitoneal [IP] vs intravenous [IV]) and BRCA status (BRCA1/2 mutated vs. BRCA wild type [WT]).
Br J Surg
March 2024
Molecular Medicine Unit-Department of Medicine, Institute of Biomedical Research of Salamanca (IBSAL) and Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-SACYL-CSIC, Salamanca, Spain.